Abstract:
Venture capitalists have argued that many nanotech concerns, like biotechs before them, will come to the public markets early in their lifetimes because their work is so capital-intensive that they'll need the kind of resources only Wall Street can provide. But so far, the market isn't ready to bet aggressively on early-stage research many institutional investors barely grasp.